1 / 11

INFLUENZA A periodic global threat

INFLUENZA A periodic global threat. Influenza vaccine. MMWR 2003; 52:987-92 INFLUENZA: the leading cause of vaccine-preventable deaths in the United States. Influenza vaccine. Four generations Killed vaccine - past (present) Split vaccine - present (future)

marla
Download Presentation

INFLUENZA A periodic global threat

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. INFLUENZA A periodic global threat

  2. Influenza vaccine MMWR 2003; 52:987-92 INFLUENZA: the leading cause of vaccine-preventable deaths in the United States

  3. Influenza vaccine Four generations • Killed vaccine - past (present) • Split vaccine - present (future) • Live vaccine - (present) future • DNA vaccine - future (potential)

  4. Influenza vaccinationof HCW at Schneider Parameter %reduction • Number sick 25% • Sickness events 35% • Fever >38.5 38% • Days sick 50%

  5. Influenza vaccinationof >65y, Maccabi HO Shapiro, IMAJ 10/03 • Cohort of 84,613, 43% vaccinated • Vaccination: 30% reduction in hospitalizations 70% in mortality • NNT to prevent hospitalization: 53 • To prevent 1 hosp d in high risk group: 1 vaccine

  6. Efficacy of live-attenuated influenza vaccine NEJM 1999; 338:1405-12 • 288 vaccinees, 2 doses (2m) • Monitored over influenza season • Culture-proven influenza: 14 vs 95 cases , efficacy 93% (88%-96%) 89% - one dose

  7. Live-attenuated cold-adaptedreassorted influenza vaccine Childhood study in Israel • Double-blind, placebo-controlled study of 420 children (6m-3y) attending DCC followed 2 winters, after boosting • Culture-proven influenza: 13.4%-32.1%!!! • Efficacy: Influenza 82%-84% Influenza-associated AOM 91% Work missed 39%

  8. INFLUENZA A periodic global threat • A new pandemic – WHEN?? • Vaccine:H1N1, H3N2,B • Hong Kong, S/E Asia, Holland • A/H5N1, H7N7

  9. WHY DNA INFLUENZA VACCINE? • Genetic drift or shift - mutations in envelope proteins • DNA vaccine - nucleoprotein(core) or matrix genes, similar in many strains • Heterotypic protection • Lifelong protection • Induced cellular & humoral immunity

  10. DNA VACCINE

  11. DNA INFLUENZA VACCINE CMJ 1/04, Vaccine 2/03, EID 8/02 Heterotypic protection • Experimental challenge in mice • Conserved nucleoprotein and matrix from H1N1 strain (plasmid) in mice, challenge by H5N1 • In pigs – priming with DNA vaccine, boosting with killed virus

More Related